1-11 of 11
Parameswaran Hari, MD MS
Close
Sort by
Journal Articles

Trends in Pre- and Post-Transplant Therapies Prior to First Autologous Hematopoietic Cell Transplantation Among Patients with Multiple Myeloma in the United States, 2004-2014

Anita D'Souza, MD, Jiaxing Huang, Mingwei Fei, MS, Parameswaran Hari, MD MS
Journal: Blood
Blood (2016) 128 (22): 677.
https://doi.org/10.1182/blood.V128.22.677.677
Published: 2016
Journal Articles

Busulfan / Melphalan / Bortezomib (Bu-Mel-Vel) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)

Tulio E. Rodriguez, MD, Parameswaran Hari, MD, MS, Patrick J Stiff, MD, Xiaobo Zhong, MS, Danielle Sterrenberg, MD, David H. Vesole, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3357.
https://doi.org/10.1182/blood.V122.21.3357.3357
Published: 2013
Journal Articles

Multiple Myeloma (MM) In Older (>70 year) Patients - Similar Benefit From Autologous Hematopoietic Cell Transplantation (AHCT) Compared With Younger Patients

Manish Sharma, MD, Mei-Jie Zhang, PhD, Xiaobo Zhong, MS, Cristina J. Gasparetto, MD, Amrita Y. Krishnan, MD, Sagar Lonial, M.D., Parameswaran Hari, MD, MS
Journal: Blood
Blood (2013) 122 (21): 416.
https://doi.org/10.1182/blood.V122.21.416.416
Published: 2013
Journal Articles

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Paul G. Richardson, MD, Arnon Nagler, MD, MSc, Dina Ben-Yehuda, MD, Ashraf Badros, MD, Parameswaran Hari, MD, MS, Roman Hajek, MD, PhD, Ivan Spicka, MD, Hakan Kaya, MD, Richard Le Blanc, MD, Sung-Soo Yoon, Kihyun Kim, MD, PhD, Joaquin Martinez-Lopez, Moshe Mittelman, MD, Ofer Shpilberg, MD, MPH, Elena Tothova, MD, Jacob P. Laubach, MD, Irene M. Ghobrial, MD, Merav Leiba, MD, Moshe E. Gatt, MD, Peter Sportelli, Michael Chen, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2013) 122 (21): 3189.
https://doi.org/10.1182/blood.v122.21.3189.3189
Published: 2013
Journal Articles

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Shaji Kumar, MD, Ian W Flinn, MD, PhD, Stephen J. Noga, MD, PhD, Parameswaran Hari, MD, MS, Robert M. Rifkin, MD, Natalie Scott Callander, MD, Manish Bhandari, MD, Jeffrey Lee Wolf, MD, Cristina Gasparetto, MD, Amrita Krishnan, MD, FACP, Daren D Grosman, MD, PhD, Jonathan Glass, MD, Entezam Asim Sahovic, MD, Hongliang Shi, MS, Iain J. Webb, MD, Paul Richardson, MD, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2008) 112 (11): 93.
https://doi.org/10.1182/blood.V112.11.93.93
Published: 2008
Journal Articles

Similar Outcomes among African-Americans (AA) and Whites after Autologous Hematopoietic-Cell Transplantation (Auto HCT) for Multiple Myeloma (MM)

Parameswaran Hari, MD, MS, Navneet S. Majhail, MD, MS, Anna Hassebroek, MPH, Mei-Jie Zhang, PhD, Fareeha Siddiqui, MD, Paulette Mehta, MD
Journal: Blood
Blood (2008) 112 (11): 740.
https://doi.org/10.1182/blood.V112.11.740.740
Published: 2008
Journal Articles

Outcome of Patients with IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplants: A Retrospective CIBMTR Study.

Donna E. Reece, MD, David H. Vesole, MD, PhD, Smriti Shrestha, MS, MA, Angela Dispenzieri, M.D., Gustavo Milone, MD, Waleska S. Peréz, MPH, Mei-Jie Zhang, PhD, Parameswaran Hari, MD, MS
Journal: Blood
Blood (2008) 112 (11): 3328.
https://doi.org/10.1182/blood.V112.11.3328.3328
Published: 2008
Journal Articles

Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) for Multiple Myeloma (MM): An Analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR).

Dan T. Vogl, MD, Waleska S. Peréz, MPH, Tao Wang, PhD, Edward A. Stadtmauer, MD, Angela Dispenzieri, MD, Gustavo Milone, MD, Donna E. Reece, MD, Parameswaran Hari, MD, MS
Journal: Blood
Blood (2008) 112 (11): 3333.
https://doi.org/10.1182/blood.V112.11.3333.3333
Published: 2008
Journal Articles

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael Pulsipher, MD, Parameswaran Hari, MD, MS, Richard Thomas Maziarz, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick Appelbaum, MD, William Bensinger, MD, Brenda Sandmaier, MD, PhD, Rainer Storb, MD, David G. Maloney, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1130.
https://doi.org/10.1182/blood.V112.11.1130.1130
Published: 2008
Journal Articles

HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM).

Meral Beksac, MD, Martin Maiers, Loren Gragert, Stephen Spellman, Smriti Shrestha, MS, MA, Mei-Jie Zhang, PhD, Angela Dispenzieri, MD, Donna E. Reece, MD, David H. Vesole, MD, PhD, Parameswaran Hari, MD, MS
Journal: Blood
Blood (2008) 112 (11): 1688.
https://doi.org/10.1182/blood.V112.11.1688.1688
Published: 2008
Journal Articles

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL)

Cesar O Freytes, MD, Jeanette Carreras, MPH, Mei-Jie Zhang, PhD, Ginna G. Laport, MD, Koen Van Besien, MD, Hillard M. Lazarus, MD, Parameswaran Hari, MD, MS
Journal: Blood
Blood (2008) 112 (11): 459.
https://doi.org/10.1182/blood.V112.11.459.459
Published: 2008